⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka Elizabeth A. Daugherity Amanda L. McCormick Trevor S. Anderson Savanna L. Smith Caryn Lawrence Duke Appiah Devin B. Lowe

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The bispecific antibody enhances the antitumor effects of regorafenib against colon cancer.
KEY EVIDENCE: Binding of the bispecific antibody to PD-L1 on tumor cells is confirmed after treatment with regorafenib.
APPROACH: The analysis involved examining the interaction of bsAb with PD-L1 and regorafenib in colon cancer cells.
SIGNIFICANCE: This work suggests new therapeutic strategies combining regorafenib and bispecific antibodies in treating colon cancer.

Implication

Supplementary figure shows bsAb binds PD-L1 on tumor cells after regorafenib exposure, suggesting enhanced efficacy.

Abstract

Supplementary Figure 3 indicates bsAb binding PD-L1 on tumor cells after exposure to REG.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d01c3 https://doi.org/10.1158/1535-7163.29760647

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
2Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
3Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
4Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
5Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025

Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025